Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.

[1]  P. Gibbs,et al.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.

[2]  D. Jäger,et al.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Herbst,et al.  Health‐Related Quality of Life in KEYNOTE‐010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  P. Heudtlass,et al.  Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study , 2019, Journal of Cancer Research and Clinical Oncology.

[5]  Donna Niedzwiecki,et al.  Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  U. Hänninen,et al.  Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy , 2019, Acta oncologica.

[7]  Prashanth Rawla,et al.  Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors , 2019, Przeglad gastroenterologiczny.

[8]  S. Culine,et al.  Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Pavlakis,et al.  Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. , 2017, The Cochrane database of systematic reviews.

[11]  M. Overman,et al.  Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Ando,et al.  Quality of Life Analysis in Patients With RAS Wild‐Type Metastatic Colorectal Cancer Treated With First‐Line Cetuximab Plus Chemotherapy , 2017, Clinical colorectal cancer.

[13]  E. Van Cutsem,et al.  Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report , 2017, Cancers.

[14]  J. Chen,et al.  Methodological and Reporting Quality of Comparative Studies Evaluating Health-Related Quality of Life of Colorectal Cancer Patients and Controls: A Systematic Review , 2016, Diseases of the colon and rectum.

[15]  A. Hauschild,et al.  Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. , 2016, European journal of cancer.

[16]  H. Dosaka-akita,et al.  Role of targeted therapy in metastatic colorectal cancer , 2016, World journal of gastrointestinal oncology.

[17]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Tabernero,et al.  Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial , 2016, ESMO Open.

[19]  K. Kahn,et al.  Symptom prevalence in lung and colorectal cancer patients. , 2015, Journal of pain and symptom management.

[20]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[21]  E. Van Cutsem,et al.  Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. , 2013, European journal of cancer.

[22]  P. Fayers,et al.  Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2012, European journal of cancer.

[23]  P. Fayers,et al.  Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. , 2009, European journal of cancer.

[24]  D. Cella,et al.  Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. , 2008, The oncologist.

[25]  M. Neary,et al.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.

[26]  Aki Tsuchiya,et al.  A single European currency for EQ-5D health states , 2003, The European Journal of Health Economics, formerly: HEPAC.

[27]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[28]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.